NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

Flaskworks may have been referenced in the original submission, but before SI 2025/87, MHRA had no legal framework to approve it as part of a modular Control Site. That regulation was laid before Parliament on June 17, which gave MHRA visibility into how to structure the license, but it does not legally come into force until July 23. That matters because under existing rules, approving DCVax-L with Flaskworks before that date would not have been possible without triggering a post-approval variation.

And this would not be a minor change. A switch from manual batch processing to Flaskworks automation qualifies as a Type II major variation. That means new comparability studies, new process validation, possible facility inspection, and months of additional review. This is standard procedure under EU and UK variation guidelines when the manufacturing process changes significantly after approval. It does not restart the MAA, and I have said that before, which remains true, but it does introduce delays, regulatory burden, and risk of refusal if the new platform is not fully justified. That is why most sponsors try to avoid major manufacturing changes immediately after approval unless they are baked into the license from the start.

In addition, SI 2025/87 also provides a tailored exemption for labeling and packaging. Under standard MHRA rules, mock-up packaging is required and patient names are generally prohibited on-label. SI 2025/87 creates an exemption for autologous therapies returned post-GMP and used immediately under the Specials route. It allows patient-specific identifiers, including name and unique ID, to appear on packaging. This matches exactly how DCVax-L is administered. Without the regulation in force, this labeling would not be allowed and would need to be addressed as part of a separate variation.

What SI 2025/87 allows is for both Flaskworks and patient-specific labeling to be validated up front under a unified legal and regulatory structure. The regulation defines Control Sites and Modular Units and enables approval of scalable platforms using a master file. The time between June 17 and July 23 gave MHRA and NWBO a quiet legal runway to finalize the entire license, align packaging and manufacturing with the new rules, and hold approval until it could be issued cleanly under that framework. No variation. No revalidation. No labeling conflict. That is not delay. That is controlled execution and strategic alignment with the law.